Cardiome Pharma Corp (COM) Insider Acquires C$35,200.00 in Stock
Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) insider Justin Renz purchased 10,000 shares of Cardiome Pharma Corp stock in a transaction that occurred on Wednesday, May 17th. The shares were bought at an average price of C$3.52 per share, with a total value of C$35,200.00.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/05/19/cardiome-pharma-corp-com-insider-acquires-c35200-00-in-stock.html.
Separately, HC Wainwright restated a “buy” rating on shares of Cardiome Pharma Corp in a research report on Wednesday.
About Cardiome Pharma Corp
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.